NCT03400306View on ClinicalTrials.gov

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 15, 2021

Primary Completion Date

November 16, 2021

Study Completion Date

November 16, 2021

Conditions
Cancer - Ovarian
Interventions
DRUG

Veliparib, capsule

capsule; 50 mg or 100 mg

DRUG

Veliparib, tablet

tablet; 400 mg

DRUG

Carboplatin

Intravenous

DRUG

Paclitaxel

Intravenous

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY